COMPASS Pathways plc (NASDAQ:CMPS) Given Consensus Rating of “Buy” by Analysts

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have been assigned a consensus rating of “Buy” from the six brokerages that are covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have covered the stock in the last year is $33.60.

CMPS has been the topic of a number of analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th. Maxim Group dropped their price objective on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, HC Wainwright cut their price objective on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, November 1st.

Institutional Investors Weigh In On COMPASS Pathways

A number of institutional investors and hedge funds have recently modified their holdings of CMPS. Hennion & Walsh Asset Management Inc. boosted its position in COMPASS Pathways by 34.7% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 148,134 shares of the company’s stock worth $933,000 after purchasing an additional 38,145 shares in the last quarter. Rosalind Advisors Inc. boosted its position in shares of COMPASS Pathways by 6.5% in the 3rd quarter. Rosalind Advisors Inc. now owns 781,423 shares of the company’s stock worth $4,923,000 after buying an additional 47,423 shares in the last quarter. Propel Bio Management LLC acquired a new stake in COMPASS Pathways in the 3rd quarter valued at about $504,000. Acuta Capital Partners LLC purchased a new position in COMPASS Pathways during the 3rd quarter valued at about $2,435,000. Finally, Walleye Capital LLC acquired a new position in COMPASS Pathways during the third quarter worth about $2,126,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

COMPASS Pathways Stock Down 4.8 %

Shares of NASDAQ:CMPS opened at $4.41 on Friday. COMPASS Pathways has a fifty-two week low of $3.16 and a fifty-two week high of $12.75. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. The firm’s 50-day simple moving average is $4.10 and its 200-day simple moving average is $5.59. The company has a market cap of $301.74 million, a price-to-earnings ratio of -2.00 and a beta of 2.28.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.